Zinacef 750 mg vial

Zinacef 750 mg vial

Zinatsef
ZINACEF

International name – cefuroxime
Classification code – J01DA06

clinical-pharmacological group – beta-lactam antibiotics (penicillins and cephalosporins); Second generation cephalosporins

Composition and release form
Powder for injection solution 750 mg: fl.

Powder for injection solution: in a vial
1 fl.
Cefuroxime
(as sodium salt). . . 750 mg

Pharmacological properties
Zinacef is a broad-spectrum antibiotic of the II generation cephalosporin group for parenteral use. The bactericidal action of Zinacef is due to the drug inhibiting the synthesis of the cell wall of microorganisms. It is resistant to most beta-lactamases.
Zinacef is active against the following microorganisms: Staphylococcus aureus (including strains resistant to penicillin, except rare strains resistant to methicillin); Staphylococcus epidermidis, Haemophilus influenzae, Klebsiella spp., Enterobacter spp., Streptococcus pyogenes, Escherichia coli, Streptococcus mitis (group viridans), Clostridium spp., Proteus mirabilis, Proteus rettgeri, Salmonella typhi, S. typhimurium and other types of Salmonella spp., Shigella spp., Neisseria spp., (including beta-lactamase-producing N. gonorrhoeae strains) and Bordetella pertusis. The drug is also active in Pr. Vulgaris, Pr. morganii strains. Most strains of Bacteroides fragilis are not sensitive to the drug. It is not active against most strains of Pseudomonas, Campilobacter, Acinobacter calcoaceticus, and Serratia, Clostridium difficile.

Pharmacokinetics
Absorption: at intramuscular injection of Zinacef, the maximum concentration of cefuroxime in the blood plasma is observed after 30-45 minutes.
Distribution: the drug passes through the blood-brain barrier. Excretion: the half-life of the drug after intramuscular and intravenous injection is about 70 minutes (3-5 times higher rate is possible in newborns). Cefuroxime is excreted unchanged by the kidneys.

testimonials
Zinacef is used to treat infectious-inflammatory diseases caused by microorganisms sensitive to the drug:
– respiratory tract infections (including acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, post-surgery infections of chest cavity organs);
– throat-ear-nose infections (sinusitis, tonsillitis, pharyngitis);
– infections of the genitourinary system (including acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria, inflammatory diseases of small pelvic organs);
– soft tissue infections (including cellulitis, scarlet fever, wound infections);
– infections of the bone-joint system (including osteomyelitis, septic arthritis);
– gonorrhea (especially in cases of increased sensitivity to antibiotics of the penicillin group);
– peritonitis; – septicemia;
– Meningitis;
– Zinacef is also used for the prevention of postoperative infections during operations on the organs of the small pelvis and abdomen, orthopedic, heart, lungs, esophagus and blood vessels.

Administration rules and dosages
Adults are prescribed 0.75-1.5 g 3 times a day for intramuscular or intravenous administration. If necessary, the interval between injections can be reduced to 6 hours; The daily dose of the drug is 3-6 g.
Children are prescribed 30-100 mcg/kg 3-4 times a day. In most cases, the optimal daily dose for infections is 60 mg/kg.
Newborns are prescribed 30-100 mg/kg 2-3 times a day. During the first week in newborns, the half-life of Zinacef in blood serum is 3-5 times longer than in adults.
In case of gonorrhea, the drug is prescribed in a dose of 1.5 g as a single injection or 750 mg as two injections in the area of both buttocks.
For meningitis, adults are prescribed 3 g intravenously every 8 hours; Children under 1 year of age and adults – 200-400 mg/kg intravenously 3-4 times a day. If the optimal therapeutic effect is achieved, the dose of the drug can be reduced to 100 mg/kg per day. The drug is prescribed to newborns in a vein with an initial daily dose of 100 mg/kg. If the optimal therapeutic effect is achieved, it is possible to reduce the intravenous dose of the drug to 50 mg/kg/day.
In order to prevent infections after abdominal, pelvic and orthopedic operations, the drug is administered intravenously at an average of 1.5 g simultaneously with drugs. If necessary, it is possible to inject additional doses of the drug into the muscles – 750 mg at 8 and 16 hours after the operation. In order to prevent infections after operations of the heart, lungs, esophagus and blood vessels, the drug is administered intravenously at an average of 1.5 g, together with drugs, during the next 24-48 hours – 750 mg 3 times a day. During total joint replacement, Zinacef powder can be mixed into each pack of polymer-methyl-methacrylate cement before adding the liquid monomer.
Patients with kidney failure, with creatinine clearance of 10-20 ml/min, are prescribed 750 mg of the drug 2 times a day; When creatinine clearance is < 10-20 ml/min, 750 mg once a day is prescribed. Dialysis patients are given an additional 750 mg after each procedure. Patients on permanent peritoneal dialysis are prescribed 750 mg 2 times a day. Method of preparation of parenteral solution:
750 mg of the drug is dissolved in 3 ml of sterile water for injection and carefully shaken until a clear mixture is formed.
Before intravenous administration, the drug is dissolved in sterile water for injection in the following ratio: 750 mg in 6 ml and 1.5 g in 15 ml.
During a short infusion (for example, up to 30 minutes), 1.5 g of the drug is dissolved in at least 50 ml of water for injection.

Side effects
Gastrointestinal tract: nausea, vomiting, diarrhea, cases of pseudomembranous colitis have been described.
From the hematopoietic system: anemia, eosinophilia, leukopenia, neutropenia.
In terms of laboratory indicators: transient increase in the content of liver transaminases, increase in blood plasma bilirubin, alkaline phosphatase activity. Allergic reactions: skin rash, itching, urticaria, fever. rarely – anaphylactic shock.
Local reactions: pain at the injection site, during intravenous injection – thrombophlebitis. A positive Coombs reaction is observed in some patients.

Contraindication
Increased sensitivity to zinacef and other beta-lactam antibiotics.

Pregnancy and lactation
The use of the drug during pregnancy has not been studied, so its appointment is recommended only when the beneficial effect for the mother clearly outweighs the potential risk of negative effects on the fetus.
It is excreted in breast milk, therefore, in case of need to use the drug during lactation, breastfeeding should be stopped.

Special instructions
The drug is prescribed with caution to patients with increased sensitivity to antibiotics of the penicillin group.
Against the background of zinacef, it is recommended to use glucokinase or hexokinase to determine the level of glucose in the blood.
The drug does not affect the result of the test for determination of creatinine with alkaline picrate.

overdose
Information on Zinacef overdose is not available.

Interaction with other drugs
Simultaneous use of zinacef with antibiotics of the aminoglycoside group and metronidazole is possible.
Zinacef is prescribed with caution in combination with furosemide.

Storage conditions and terms
The drug is stored in a dry place at a temperature not exceeding 25°C.

Country of manufacture
Great Britain